NZ754427A - Regulation of glucose metabolism using anti-cgrp antibodies - Google Patents

Regulation of glucose metabolism using anti-cgrp antibodies

Info

Publication number
NZ754427A
NZ754427A NZ754427A NZ75442714A NZ754427A NZ 754427 A NZ754427 A NZ 754427A NZ 754427 A NZ754427 A NZ 754427A NZ 75442714 A NZ75442714 A NZ 75442714A NZ 754427 A NZ754427 A NZ 754427A
Authority
NZ
New Zealand
Prior art keywords
cgrp antibody
hepatic glucose
glucose utilization
peripheral
optionally
Prior art date
Application number
NZ754427A
Other languages
English (en)
Inventor
Jeffrey T L Smith
John A Latham
Brian Baker
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Priority claimed from NZ715834A external-priority patent/NZ715834B2/en
Publication of NZ754427A publication Critical patent/NZ754427A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
NZ754427A 2013-07-03 2014-07-03 Regulation of glucose metabolism using anti-cgrp antibodies NZ754427A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842745P 2013-07-03 2013-07-03
US201461982611P 2014-04-22 2014-04-22
NZ715834A NZ715834B2 (en) 2013-07-03 2014-07-03 Regulation of glucose metabolism using anti-cgrp antibodies

Publications (1)

Publication Number Publication Date
NZ754427A true NZ754427A (en) 2021-12-24

Family

ID=52144290

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ754427A NZ754427A (en) 2013-07-03 2014-07-03 Regulation of glucose metabolism using anti-cgrp antibodies

Country Status (14)

Country Link
US (1) US20150017166A1 (https=)
EP (1) EP3016684B1 (https=)
JP (4) JP6502337B2 (https=)
KR (1) KR102476907B1 (https=)
CN (1) CN105492026B (https=)
AU (2) AU2014285052B2 (https=)
CA (1) CA2916980C (https=)
ES (1) ES2911690T3 (https=)
IL (1) IL243355B2 (https=)
MX (1) MX374612B (https=)
NZ (1) NZ754427A (https=)
SG (2) SG10201906172XA (https=)
TW (2) TWI712419B (https=)
WO (1) WO2015003122A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL243355B2 (en) * 2013-07-03 2024-10-01 Lundbeck Seattle Biopharmaceuticals Inc Regulation of glucose metabolism using anti-cgrp antibodies
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
CA3077973A1 (en) 2020-04-06 2021-10-06 H. Lundbeck A/S Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
CN116057185A (zh) * 2020-08-15 2023-05-02 雷杰纳荣制药公司 治疗具有编码降钙素受体(calcr)的变体核酸分子的受试者的肥胖症
IL310885A (en) 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-CGRP antibodies
US20260001942A1 (en) 2024-06-21 2026-01-01 H. Lundbeck A/S Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5364841A (en) * 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
AU631112B2 (en) * 1988-01-11 1992-11-19 Amylin Corporation Treatment of type 2 diabetes mellitus
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JPH0666358B2 (ja) * 1989-01-03 1994-08-24 モトローラ・インコーポレーテッド 高密度ソルダ・バンプの製造方法と高密度ソルダ・バンプ用基板ソケット
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
ES2080802T3 (es) * 1989-07-10 1996-02-16 Amylin Pharmaceuticals Inc Uso de un antagonista de amilina en la preparacion de un medicamento para el tratamiento de la obesidad e hipertension intrinseca y desordenes asociados.
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
EP1461068A4 (en) * 2001-11-26 2006-03-29 Protemix Corp Ltd METHOD AND COMPOSITIONS FOR NORMALIZING LIPID MIRRORS IN MIRACLE TISSUE
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
EP3069731A1 (en) * 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP2021463B1 (en) 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
PE20141787A1 (es) * 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
TWI705825B (zh) * 2011-05-20 2020-10-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）或抗降血鈣素基因相關胜肽受器（ａｎｔｉ－ｃｇｒｐ－ｒ）抗體或抗體片段治療或預防慢性及急性型腹瀉之用途
IL243355B2 (en) * 2013-07-03 2024-10-01 Lundbeck Seattle Biopharmaceuticals Inc Regulation of glucose metabolism using anti-cgrp antibodies

Also Published As

Publication number Publication date
KR20160029822A (ko) 2016-03-15
JP6502337B2 (ja) 2019-04-17
CA2916980A1 (en) 2015-01-08
SG10201906172XA (en) 2019-08-27
SG11201510618YA (en) 2016-03-30
IL243355B1 (en) 2024-06-01
AU2014285052B2 (en) 2019-09-12
WO2015003122A2 (en) 2015-01-08
EP3016684A2 (en) 2016-05-11
WO2015003122A3 (en) 2015-03-19
JP2018168186A (ja) 2018-11-01
AU2014285052A1 (en) 2016-02-11
ES2911690T3 (es) 2022-05-20
TWI753471B (zh) 2022-01-21
AU2019279945A1 (en) 2020-01-16
CA2916980C (en) 2023-02-21
TWI712419B (zh) 2020-12-11
IL243355A0 (en) 2016-03-31
MX2016000220A (es) 2016-08-18
CN105492026A (zh) 2016-04-13
JP2016528198A (ja) 2016-09-15
KR102476907B1 (ko) 2022-12-13
TW202106335A (zh) 2021-02-16
US20150017166A1 (en) 2015-01-15
NZ715834A (en) 2021-11-26
AU2019279945B2 (en) 2022-01-20
JP2019112455A (ja) 2019-07-11
EP3016684A4 (en) 2017-06-07
EP3016684B1 (en) 2022-02-23
TW201536316A (zh) 2015-10-01
JP2020158525A (ja) 2020-10-01
CN105492026B (zh) 2025-12-30
MX374612B (es) 2025-03-06
IL243355B2 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
NZ754427A (en) Regulation of glucose metabolism using anti-cgrp antibodies
NZ716473A (en) Diagnosis and therapy of cancer involving cancer stem cells
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
MX2025010483A (es) Uso de anticuerpos y composiciones que los comprenden para tratar enfermedades y trastornos mediados por complemento
BR112017011536A2 (pt) terapias de combinação
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
WO2014080286A3 (en) Methods and compositions for treating multiple sclerosis and related disorders
SG195191A1 (en) Methods and compositions of predicting activity of retinoid x receptor modulator
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
EA201290883A1 (ru) Способы диагностики и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака
WO2009073544A3 (en) Methods for treating a disorder by regulating gprc6a
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EA201300133A1 (ru) Фармацевтическая композиция и способ лечения ожирения, сопутствующих метаболических расстройств и зависимости от психоактивных веществ
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
EP3988673A3 (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
PH12013500111A1 (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
HK1198135A1 (en) Prevention and treatment of pain using antibodies to lysophosphatidic acid
MX2015015519A (es) Regulador de papalisina.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: H. LUNDBECK A/S, DK

Effective date: 20211105

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2023 BY AJ PARK

Effective date: 20220503

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2024 BY CPA GLOBAL

Effective date: 20230518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240516

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUL 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250522